RT期刊文章SR电子T1 Non-Amnestic轻度认知障碍的进展与路易体痴呆(S24.002)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S24.002 OP S24.002 VO 80是7补充A1坦尼斯Fe首页rman A1格伦·史密斯A1 V。Shane Pankratz说道A1 Kejal Kantarci A1布拉德利Boeve A1尼尔Graff-Radford A1瑞安Uitti A1兹比格涅夫•Wszolek A1杰伊·范Gerpen A1奥托佩德拉泽A1 David Knopman A1丹尼斯·迪克森A1罗纳德·彼得森年2013 UL //www.ez-admanager.com/content/80/7_Supplement/S24.002.abstr首页act AB目的:确定进展的速度从轻度认知障碍(MCI)和路易体痴呆(下文)。背景:MCI代表了早期认知功能障碍的人最终发展成老年痴呆症。设计/方法:我们确定了连续患者随纵向从梅奥与诊断阿尔茨海默病研究中心的单一或多域,遗忘或non-amnestic MCI。所有患者接受年度正式神经认知评估。年度informant-based完成日常生活活动量表。下文或AD进展诊断使用建立标准估计每100人年的随访中,事件发生率和组间相比,使用密度的方法。结果:337名患者初步诊断为MCI, 116年仍作为MCI, 49进展下文,162年发展为广告,和10个发展到其它痴呆。患者随访2至12年。那些发展为痴呆没有后续年差异(5.2±2.5年),或年龄(73.5±7.5年)。下文群大多为男性(下文83.7%比广告51.9%比60%)。Non-amnestic(单一或多域)MCI发展到下文的速度每100人年,23.3事件和广告的速度每100人年2.1事件。 Amnestic MCI (single or multi-domain) progressed to DLB at an annual rate of 1.0 events per 100 person years, and to AD at a rate of 17.1 events per 100 person years. The non-amnestic domains in those progressing to DLB represented attention and visuospatial skills.CONCLUSIONS: Patients with non-amnestic MCI (single or multi-domain) were more likely to develop DLB than AD, and conversely, patients with amnestic MCI were more likely to develop AD.Supported by: National Institutes of Health: R01-AG015866, P50-AG16574, Mangurian Foundation for Lewy body dementia research, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program.Disclosure: Dr. Ferman has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Pankratz received financial support for research activities from Abbott Laboratories. Dr. Kantarci has received compensation from Takeda Global Research & Development Center for serving as an advisory board member for research support. Dr. Boeve has received research support from Cephalon, Inc.; Allon Therapeutics; and GE Healthcare. Dr. Graff-Radford has received personal compensation for activities with Codman. Dr. Graff-Radford has received personal compensation in an editorial capacity for the Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Pharmaceuticals, Medivation, Forrest, and Allon. Dr. Uitti has received personal compensation in an editorial capacity for Neurology. Dr. Uitti has received research support from NINDS, Mayo Clinic, and St. Jude Medical. Dr. Wszolek has received personal compensation in an editorial cqapacity for Parkinsonism and Related Disorders and the European Journal of Neurology. Dr. Wszolek has received research support from the NIH/NINDS, Mayo Clinical Florida Research Committee CR Program, and Dystonia Medical Research Foundation. Dr. Van Gerpen has nothing to disclose. Dr. Pedraza has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from TauRx. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, GE Healthcare, and Novartis.Wednesday, March 20 2013, 2:00 pm-3:45 pm